Olaf Mundigl

This inventor holds 36 USPTO granted patents and 7 published patent applications, plus 8 CIPO patents and 14 EPO patents, primarily in Bispecific Antibodies. Top assignees: Hoffmann-La Roche Inc., Prothena Biosciences Limited, Roche Glycart Ag. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olaf Mundigl. Retrieved from https://idiyas.com/inventor/olaf-mundigl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 7)

% Patents Active = 58.3

CIPO Patents = 8 (Patent Applications = 6)

EPO Patents = 14 (Patent Applications = 23)

Average Co-Inventor Count = 6.2

ph-index = 7

Forward Citations = 159(Granted Patents)

Location History:

Polling, DE (2003)
Weilhem, DE (2017 - 2019)
Weilheim, DE (2004 - 2023)
Penzberg, DE (2021 - 2024)

Company Filing History:

35 out of 5,026

Hoffmann-La Roche Inc.

patents

1 out of 64

Prothena Biosciences Limited

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Blood-Brain Barrier

Humanized Antibodies

Anti-Tau Antibodies

VEGF Antibodies

Alpha-Synuclein Antibodies

IL-1beta Antibodies

EPO Receptor Antibodies

Therapeutic Agents

Diagnostic Agents

Histone Deacetylase Inhibitors

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297263 - Humanized anti-Tau(PS422) antibodies and methods of use (2025-05-13),

2. 11866490 - Antibody that binds to VEGF and IL-1beta and methods of use (2024-01-09),

3. 11572404 - Humanized anti-Tau(pS422) antibodies and methods of use (2023-02-07),

4. 11273223 - Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles (2022-03-15),

5. 11130804 - Antibody that binds to VEGF and IL-1beta and methods of use (2021-09-28),

6. 10822402 - Humanized anti-tau(pS422) antibodies and methods of use (2020-11-03),

7. 10806795 - Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles (2020-10-20),

8. 10730938 - Bispecific antibodies and methods of use in ophthalmology (2020-08-04),

9. 10647761 - Anti-alpha-synuclein antibodies and methods of use (2020-05-12),

10. 10562973 - Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein (2020-02-18),

11. 10561737 - Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles (2020-02-18),

12. 10465000 - Humanized anti-Tau(pS422) antibodies and methods of use (2019-11-05),

13. 10344085 - Anti-IL-1beta antibodies (2019-07-09),

14. 10316082 - Anti-alpha-synuclein antibodies and methods of use (2019-06-11),

15. 10087246 - Anti-PDGF-B antibodies and methods of use (2018-10-02),

Title: Olaf Mundigl: A Visionary Inventor Shaping the Future of Technology

Introduction:

Olaf Mundigl, a dedicated inventor hailing from Weilheim, DE, has left an indelible mark on the world of technology through his relentless pursuit of innovation. With a total of 35 patents to his name, Mundigl's pioneering spirit continues to inspire the next generation of inventors to push the boundaries of what is possible.

Latest Patents:

Among Mundigl's latest patents are groundbreaking inventions such as the "Antibody that binds to VEGF and IL-1beta," opening new possibilities in the field of medicine. Furthermore, his creation of "Humanized anti-Tau(pS422) antibodies" showcases his commitment to advancing neurology and medical research.

Career Highlights:

Throughout his illustrious career, Olaf Mundigl has made significant contributions while working at Hoffmann-la Roche Inc., establishing himself as a key figure in the cutting-edge research and development initiatives of the company. His innovative ideas and patent filings have demonstrated his exceptional talent and vision in the realm of technology.

Collaborations:

Collaborating with esteemed colleagues such as Guy Georges and Stefan Dengl, Mundigl has been able to amplify the impact of his inventions and bring them to fruition. These partnerships have played a crucial role in the successful development and implementation of his patented technologies.

Conclusion:

In conclusion, Olaf Mundigl's legacy as a visionary inventor is characterized by his unwavering dedication to driving innovation and shaping the future of technology. His numerous patents and contributions serve as a testament to his profound impact on the world of science and technology, inspiring others to follow in his footsteps and push the boundaries of what is possible.Dot

Profile summary based on public USPTO records.